stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 28
- 主要终点
- progression free survival
研究概览
简要总结
Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥18 years
- •Histological diagnosis of breast cancer
- •Oligometastatic or oligoprogressive metastatic breast cancer
- •SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition
- •Ability to provide written informed consent
排除标准
- 未提供
研究组 & 干预措施
TREATMENT SBRT
patients who have been treated with stereotactic radiotherapy to oligometastatic sites
结局指标
主要结局
progression free survival
时间窗: from January 2010 to December 2023
years of survival without disease progression assessed by imaging
次要结局
- Local Control(from January 2010 to December 2023)
- overall survival(From January 2010 to December 2023)
- acute and late toxicity RT related(from January 2010 to December 2023)
